Aug 24,2022

New digital health programme in Australia to help childhood cancer survivors be more active

A researcher from the University of New South Wales Medicine and Health has developed a digital health programme to help childhood cancer survivors get physically active. Supported by The Kids' Cancer Project, the iBounce programme had been tested through a pilot involving 30 participants from the Sydney Children's Hospital over a 12-week period. By the end of the programme, participants had shown "significant" improvements in their aerobic fitness, according to a study published in JMIR Cancer.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Aug 25,2022

Two Companies Announce Partnership to Enable Better Outcomes & Change Cancer's Impact

patients' lives. The partnership provides a unique combination of prevention, care management, and survivorship solutions along with a comprehensive cancer care app. This creates a full-service resource for cancer patients and rapidly furthers both organizations' missions to change cancer's impact.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 01,2022

Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer

Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the Roche Group, in partnership with a network of community oncology practices, today announced new research in the Journal of Thoracic Oncology Clinical and Research Reports on tumor profiling results from the ongoing, multicenter Prospective Clinicogenomic (PCG) Study (NCT04180176). In this investigation, researchers compared the ability of FoundationOne®CDx and FoundationOne®Liquid CDx comprehensive genomic profiling (CGP) to limited tissue testing in detecting actionable, guideline-recommended biomarkers for targeted treatment planning in patients with advanced non-squamous non-small cell lung cancer (aNSCLC). Results from this research reinforce that, in certain patient cases where an adequate tissue sample is immediately available, tissue CGP offers the most reliable detection of guideline-recommended biomarkers.

CLINICAL STUDY

#cdx

View Analyst & Ambassador Comments
Go to original news
Aug 22,2022

With Tailored, Fit-for-Purpose RWD from COTA, Life Science Companies Can Drive Innovation

Deeply curated, targeted oncology datasets are often hard to find, especially for life science companies on the leading edge of innovation. COTA's cancer-specific data product Vantage© offers flexible, customized, and de-identified data to equip researchers with fit-for-purpose real-world data. With deeply curated, disease-specific, large scale data sets from our Vantage© product, life science companies can leverage de-identified EHR data for a variety of high-value projects, including informing the direction of new products, conducting health economics and outcomes research, supporting regulatory submissions via external control and comparator arms (ECAs), and demonstrating value and safety in the post-market environment.

PRODUCT

#rwd

#big data

View Analyst & Ambassador Comments
Go to original news
Aug 25,2022

Massive Bio Co-Founder Dr. Arturo Loaiza-Bonilla Will Attend The “Oncología De Cara Al Futurose” Symposium As a Speaker

At the launch of the “Oncología de Cara al Futurose” symposium organized by the largest cancer research center in Latin America, Massive Bio co-founder, and Chief Medical Officer Dr. Arturo Arturo Loaiza-Bonilla will be the speaker.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Aug 29,2022

Proteins provide clue to predict cancer treatment outcome

Binyamina-based OncoHost is developing a platform that can predict exactly who will respond to what treatment. The company has raised $50 million to launch its PROphet system which, if it works as promised, could significantly aid physicians, cut clinic costs and, most importantly, reduce unnecessary deaths due to picking the wrong pharma horse to bet on.

View Analyst & Ambassador Comments
Go to original news
Sep 05,2022

Results presented at ESMO 2022: Kaiku Health digital patient monitoring platform can help in resolving acute fever in melanoma patients

A multicenter study led by the Netherlands Cancer Institute used Kaiku Health digital patient management platform to investigate the use of digital patient monitoring and support of patients with advanced melanoma. The results published at ESMO 2022 annual conference suggest that Kaiku Health can be used to support patients and to collect real-world evidence. They can also help to understand the development of symptoms and quality of life of the patients. The study was a part of the Kaiku Health and Novartis collaboration announced in 2021. The results will be presented at the ESMO 2022 annual conference on Saturday, September 10, by the first author Judith Lijnsvelt from the Netherlands Cancer Institute.

CLINICAL STUDY

#ml

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 28,2022

Machine Learning Creates Opportunity for New Personalized Therapies

Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

Ibex reports positive outcomes for AI-based breast cancer diagnostic

Ibex Medical Analytics announced today that a study of its Galen Breast diagnostic offering delivered positive outcomes. Tel Aviv, Israel-based Ibex designed its Galen platform to support pathologists in diagnosing breast, prostate, and gastric biopsies. Galen uses AI and machine learning technology based on hundreds of thousands of image samples scanned from biopsy slides through digital pathology.

PRODUCT

#ml

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 08,2022

How An A.I.-Based Skin Checking App Can Work With A National Healthcare System

AIP Labs and Semmelweis University (Hungary’s leading medical university) developed a skin checking application that offers several features we have not seen before. It was launched to work integrated with the national healthcare system and offer full-scope dermatology services including diagnostics, treatment plans and cloud-based drug subscriptions. According to currently available data, processing speeds have improved by 5-10 times compared to the traditional care model.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY